Abstract Library

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,

#2156 Two Cases Synchronous Atypical Parathyroid Adenomas and Papillary Thyroid Carcinoma

Introduction: A literature review revealed a prevalence of approximately 3% of nonmedullary thyroid cancer, which was found in patients operated on for primary hyperparathyroidism (pHPT). Papillary thyroid carcinomas(PTC) is a malignant epithelial tumour. PTC represent up to 87% of all thyroid carcinomas. Atypical parathyroid adenoma(APA) are a subset of parathyroid neoplasms that exhibit some of the features of parathyroid carcinoma but lack unequivocal invasive growth. APA represents about 0,5-4% of cases of pHPT. As a group, they may be considered tumors of uncertain malignant potential.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Voronkova I, Mokrysheva N, Lapshina A, Gurevich L, Britvin T,

Keywords: papillary thyroid carcinomas, atypical parathyroid adenoma, primary hyperparathyroidism,

#1921 Prognostic Factors That Mandate Long Term Follow Up Following Surgery for Appendiceal Neuroendocrine Tumours (aNETs)

Introduction: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy and rarely recur. Current ENET guidelines inform their management and highlight areas of uncertainty.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Alabraba E, Banks M, Malik H, Fenwick S, Cuthbertson D,

Keywords: Appendix NET,

#1860 Carcinoid Heart Disease (CHD): Prognostic Value of 5-HIAA and Impact on Survival – A Systematic Literature Review

Introduction: CHD is a life threatening complication of carcinoid syndrome. Its exact pathophysiology is uncertain but several studies have identified serotonin as a potential key mediator. The amount of serotonin production can be assessed by the dosage of its metabolite 5-HIAA in urine or plasma.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Singh S

Authors: Haig J, Kohli M, Pastor L, Feuilly M, Marteau F,

Keywords: 5-HIAA, prognosis, carcinoid heart disease, survival,

#1721 Optimisation of the Size Variation Threshold for CT Evaluation of Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors Treated with Octreotide LAR

Introduction: In advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), somatostatin analogs treatment rarely achieve a reduction of -30% in the sum of longest diameters (SLD) of target lesions required by Response Evaluation Criteria in Solid Tumors (RECIST) for an ‘objective response’. The implication of Stable Disease (SD) as an additional indicator of therapeutic effect is often uncertain.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Luo Y

Authors: Luo Y, Chen J,

Keywords: GEP-NETs, Octreotide LAR, Progression-free Survival,